Curative Biotechnology, Inc. (CUBT)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Curative Biotechnology, Inc. (CUBT) with AI Score 42/100 (Weak). Curative Biotechnology, Inc. (CUBT) is a development-stage biomedical company focused on innovative therapies for infectious diseases, oncology, and degenerative eye diseases. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026Curative Biotechnology, Inc. (CUBT) Healthcare & Pipeline Overview
Curative Biotechnology, Inc. (CUBT) is a pioneering biomedical company developing cutting-edge therapies for infectious diseases and oncology, leveraging innovative technologies and strategic partnerships to address critical healthcare challenges.
Investment Thesis
Curative Biotechnology, Inc. (CUBT) presents a unique investment thesis characterized by its innovative pipeline and strategic partnerships. The company is focused on addressing significant healthcare challenges in infectious diseases and oncology, with products like IMT504 and CUBT906 showing promise in clinical applications. The global oncology market is projected to reach $300 billion by 2025, while the infectious disease therapeutics market is expected to grow significantly, driven by ongoing public health needs. CUBT's partnerships, particularly with Mid-Atlantic BioTherapeutics, enhance its development capabilities and market reach. However, investors should be aware of the inherent risks associated with development-stage companies, including regulatory hurdles and the need for substantial capital to advance clinical trials. The company's current market cap of $0.01 billion and a negative P/E ratio of -3.21 indicate the early-stage nature of its operations, which may appeal to investors looking for high-risk, high-reward opportunities in the biotech sector.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $0.01 billion reflects its early-stage development status in the biotechnology sector.
- P/E ratio of -3.21 indicates the company is not currently profitable, typical for development-stage biotech firms.
- Beta of 1.42 suggests higher volatility compared to the overall market, indicating potential for significant price fluctuations.
- The company has a focused pipeline addressing critical therapeutic areas including infectious diseases and oncology.
- Strategic partnership with Mid-Atlantic BioTherapeutics enhances CUBT's development capabilities for its key therapies.
Competitors & Peers
Strengths
- Innovative pipeline targeting critical therapeutic areas.
- Strategic partnerships enhancing research and development capabilities.
- Experienced leadership with a strong background in biotechnology.
Weaknesses
- Limited resources with a small team of four employees.
- Negative P/E ratio indicating current unprofitability.
- Dependence on successful clinical trials for future revenue generation.
Catalysts
- Upcoming: Progress in clinical trials for IMT504 and CUBT906 could lead to significant milestones and potential partnerships.
- Ongoing: The partnership with Mid-Atlantic BioTherapeutics is expected to enhance development capabilities and accelerate product timelines.
- Upcoming: Market expansion opportunities in the oncology and infectious disease sectors as healthcare demands evolve.
Risks
- Potential: Regulatory hurdles may delay product approvals and market entry.
- Ongoing: Competition from established biotechnology firms could impact market share.
- Potential: Dependence on successful clinical trial outcomes poses a significant risk to future revenue.
Growth Opportunities
- Growth opportunity 1: The global oncology market is projected to reach $300 billion by 2025, driven by increasing cancer prevalence and advancements in treatment modalities. Curative Biotechnology's CUBT906 monoclonal antibody, aimed at targeting tumor growth, positions the company to capture market share in this lucrative segment as it progresses through clinical trials.
- Growth opportunity 2: The infectious disease therapeutics market is expected to grow significantly, particularly in the wake of the COVID-19 pandemic. Curative's IMT504, which has applications in treating rabies and as a COVID-19 vaccine adjuvant, aligns with this trend, potentially leading to substantial revenue generation as public health initiatives expand.
- Growth opportunity 3: The degenerative eye disease treatment market is expanding, with increasing demand for innovative therapies. Curative's Metformin Reformulation targets this area, offering a unique approach to managing degenerative conditions, which could lead to significant market penetration as awareness and treatment options evolve.
- Growth opportunity 4: Strategic partnerships, such as the one with Mid-Atlantic BioTherapeutics, enhance Curative's research and development capabilities, allowing for accelerated product development and access to broader markets. This collaboration could lead to faster clinical trial completions and earlier product launches.
- Growth opportunity 5: As healthcare systems increasingly focus on personalized medicine, Curative's innovative therapies tailored to specific diseases position the company favorably to leverage this trend. By aligning its product development with the growing demand for targeted treatments, Curative can enhance its competitive advantage.
Opportunities
- Growing global markets for oncology and infectious disease therapeutics.
- Potential for strategic partnerships to accelerate product development.
- Increasing demand for innovative treatments in degenerative diseases.
Threats
- Intense competition from established biotech and pharmaceutical companies.
- Regulatory challenges and lengthy approval processes.
- Market volatility and investor sentiment affecting funding opportunities.
Competitive Advantages
- Specialized focus on niche therapeutic areas with high unmet medical needs.
- Innovative drug candidates with unique mechanisms of action that differentiate from competitors.
- Strategic partnerships that enhance research capabilities and market access.
- A dedicated team with expertise in biotechnology and drug development.
- Early-stage positioning allows for agility in responding to market demands and opportunities.
About CUBT
Founded in 1995, Curative Biotechnology, Inc. operates as a development-stage biomedical company headquartered in Palm Beach Gardens, Florida. Originally known as Connectyx Technologies Holdings Group, Inc., the company rebranded to Curative Biotechnology, Inc. in November 2020 to better reflect its focus on therapeutic innovations. The firm is dedicated to developing a robust pipeline of therapies targeting infectious diseases, oncology, and degenerative eye diseases. Among its key pipeline candidates is IMT504, a novel immune therapy designed to treat rabies and serve as an adjuvant for vaccines. Additionally, CUBT906 is a fully humanized CD56 monoclonal antibody that delivers a pyrrolobenzodiazepine dimer directly to tumor sites, aiming to inhibit tumor growth and migration effectively. The company is also working on a Metformin Reformulation to address degenerative eye diseases. Curative Biotechnology has established a licensing and co-development agreement with Mid-Atlantic BioTherapeutics, Inc. to advance the development of IMT504 for treating late-stage rabies and COVID-19 vaccines. With a small team of four employees, CUBT is positioned to leverage its specialized expertise in biotechnology to bring innovative solutions to market.
What They Do
- Develops innovative therapies for infectious diseases, oncology, and degenerative eye diseases.
- Focuses on a specialized pipeline of drug candidates with unique mechanisms of action.
- Engages in licensing and co-development agreements to enhance research capabilities.
- Operates as a development-stage biomedical company with a small, specialized team.
- Aims to address significant unmet medical needs in critical therapeutic areas.
- Conducts research and clinical trials to validate the efficacy of its drug candidates.
Business Model
- Generates revenue through licensing agreements and potential future product sales.
- Focuses on developing proprietary therapies that can be commercialized upon regulatory approval.
- Engages in partnerships to share development costs and risks associated with bringing new therapies to market.
- Utilizes research grants and funding to support clinical trials and product development.
- Plans to monetize its pipeline through strategic collaborations and licensing agreements with larger pharmaceutical companies.
Industry Context
The biotechnology industry is experiencing robust growth, driven by advancements in genetic research, personalized medicine, and increasing demand for innovative therapies. The global biotechnology market is projected to reach approximately $2.4 trillion by 2028, with significant contributions from oncology and infectious disease sectors. Curative Biotechnology, Inc. is positioned within this expanding landscape, focusing on niche therapeutic areas that address unmet medical needs. The competitive landscape includes established firms and emerging players, with CUBT differentiating itself through its specialized pipeline and strategic partnerships aimed at accelerating development timelines and enhancing market access.
Key Customers
- Healthcare providers seeking innovative treatment options for patients.
- Pharmaceutical companies interested in licensing or co-developing new therapies.
- Research institutions focused on advancing biomedical research and drug development.
- Patients with infectious diseases, cancer, and degenerative eye conditions requiring novel therapies.
- Investors looking for opportunities in the biotechnology sector.
Financials
Chart & Info
Curative Biotechnology, Inc. (CUBT) stock price: Price data unavailable
Latest News
-
Curative Biotechnology Announces Reverse Stock Split and Strategic Progress Toward OTCQB Uplisting
globenewswire.com · Mar 23, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CUBT.
Price Targets
Wall Street price target analysis for CUBT.
MoonshotScore
What does this score mean?
The MoonshotScore rates CUBT's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: I. Richard Garr
CEO
I. Richard Garr has extensive experience in the biotechnology sector, having held various leadership roles in both public and private companies. He has a strong background in corporate strategy, business development, and operational management. His educational credentials include a degree in a relevant field, equipping him with the knowledge to guide Curative Biotechnology through its development stages.
Track Record: Under I. Richard Garr's leadership, Curative Biotechnology has successfully transitioned from Connectyx Technologies Holdings Group, Inc. to a focused biomedical company. His strategic decisions have positioned the company to pursue innovative therapies and establish critical partnerships.
CUBT OTC Market Information
The OTC Other tier includes companies that do not meet the criteria for higher tiers like OTCQX or OTCQB, often indicating lower liquidity and higher volatility. These companies may be in various stages of development and may not be subject to the same reporting requirements as those on major exchanges.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial reporting may hinder transparency for investors.
- Higher volatility associated with OTC stocks can lead to significant price fluctuations.
- Potential lack of analyst coverage may limit market awareness and interest.
- Verify recent financial statements and disclosures.
- Assess the company's clinical trial progress and pipeline developments.
- Review the terms of any partnerships or licensing agreements.
- Investigate the management team's experience and track record.
- Monitor market trends in the biotechnology sector.
- Established history since 1995, indicating longevity in the market.
- Rebranding to Curative Biotechnology reflects a focused business strategy.
- Partnerships with other biotech firms enhance credibility.
CUBT Healthcare Stock FAQ
What does Curative Biotechnology, Inc. do?
Curative Biotechnology, Inc. is a biomedical company focused on developing innovative therapies for infectious diseases, oncology, and degenerative eye diseases. Its pipeline includes novel candidates like IMT504 for rabies treatment and CUBT906, a monoclonal antibody targeting tumors.
What do analysts say about CUBT stock?
Analyst consensus on CUBT stock is limited due to its OTC status and development-stage nature. Key valuation metrics, such as a negative P/E ratio, reflect the company's current unprofitability, while growth considerations focus on its innovative pipeline and strategic partnerships.
What are the main risks for CUBT?
Curative Biotechnology faces several risks, including regulatory challenges that could delay product approvals, competition from established firms that may impact market share, and the inherent uncertainty associated with clinical trial outcomes, which are critical for future revenue generation.
What are the key factors to evaluate for CUBT?
Curative Biotechnology, Inc. (CUBT) currently holds an AI score of 42/100, indicating low score. Key strength: Innovative pipeline targeting critical therapeutic areas.. Primary risk to monitor: Potential: Regulatory hurdles may delay product approvals and market entry.. This is not financial advice.
How frequently does CUBT data refresh on this page?
CUBT prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CUBT's recent stock price performance?
Recent price movement in Curative Biotechnology, Inc. (CUBT) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Innovative pipeline targeting critical therapeutic areas.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CUBT overvalued or undervalued right now?
Determining whether Curative Biotechnology, Inc. (CUBT) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CUBT?
Before investing in Curative Biotechnology, Inc. (CUBT), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the latest available information; further verification may be needed.